

IMMUNOMEDICS INC
Form 8-K
August 07, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 4, 2009

Immunomedics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-12104
(Commission File Number)

61-1009366
(IRS Employer
Identification No.)

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

300 American Road, Morris Plains, New Jersey
(Address of Principal Executive Offices)

(973) 605-8200

07950
(Zip Code)

(Registrant's telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 1.01. Entry into a Material Definitive Agreement.

On August 4, 2009, Immunomedics, Inc., a Delaware corporation (the Company), received a letter, dated July 30, 2009, from UCB, S.A. (UCB) stating that UCB has identified a third party manufacturer for epratuzumab and therefore relieved the Company of its obligation to supply to UCB Licensed Product (as defined in that certain Development, Collaboration and License Agreement, dated as of May 9, 2006, between the Company and UCB (the Agreement)) pursuant to Section 4.3 of the Agreement for use in clinical trials for systemic lupus erythematosus. All other terms of the Agreement remain in effect.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNOMEDICS, INC.

By: /s/ Gerard G. Gorman

Name: Gerard G. Gorman

Title: Senior Vice President, Finance and Business
Development and Chief Financial Officer

Date: August 7, 2009